Syndax Pharmaceuticals (SNDX) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

SNDX Stock Forecast

Syndax Pharmaceuticals stock forecast is as follows: an average price target of $31.67 (represents a 142.13% upside from SNDX’s last price of $13.08) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.

SNDX Price Target

The average price target for Syndax Pharmaceuticals (SNDX) is $31.67 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $37.00 to $18.00. This represents a potential 142.13% upside from SNDX's last price of $13.08.

SNDX Analyst Ratings

Buy

According to 10 Wall Street analysts, Syndax Pharmaceuticals's rating consensus is 'Buy'. The analyst rating breakdown for SNDX stock is 0 'Strong Buy' (0.00%), 9 'Buy' (90.00%), 1 'Hold' (10.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

Syndax Pharmaceuticals Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Nov 13, 2024	George Farmer	Scotiabank	$18.00	$20.04	-10.18%	37.61%
Oct 24, 2024	David Dai	UBS	$37.00	$18.54	99.57%	182.87%
Aug 15, 2024	Yigal Nochomovitz	Citigroup	$34.00	$20.09	69.24%	159.94%
Aug 15, 2024	Jason Zemansky	Bank of America Securities	$31.00	$19.58	58.32%	137.00%
Aug 15, 2024	Peter Lawson	Barclays	$33.00	$19.58	68.54%	152.29%
Jul 30, 2024	Jason Zemansky	Bank of America Securities	$30.00	$21.99	36.43%	129.36%
Jun 28, 2024	Kelly Shi	Jefferies	$37.00	$20.32	82.09%	182.87%
May 09, 2024	Bradley Canino	Stifel Nicolaus	$40.00	$22.38	78.73%	205.81%
Jan 03, 2023		J.P. Morgan	$41.00	$26.32	55.75%	213.46%
Dec 12, 2022		Goldman Sachs	$39.00	$23.39	66.74%	198.17%
Dec 12, 2022		H.C. Wainwright	$33.00	$20.64	59.88%	152.29%

The latest Syndax Pharmaceuticals stock forecast, released on Nov 13, 2024 by George Farmer from Scotiabank, set a price target of $18.00, which represents a -10.18% decrease from the stock price at the time of the forecast ($20.04), and a 37.61% increase from SNDX last price ($13.08).

Syndax Pharmaceuticals Price Target by Period

	1M	3M	12M
# Anlaysts	-	2	8
Avg Price Target	-	$27.50	$32.50
Last Closing Price	$13.08	$13.08	$13.08
Upside/Downside	-100.00%	110.24%	148.47%

In the current month, the average price target of Syndax Pharmaceuticals stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Syndax Pharmaceuticals's last price of $13.08. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Nov 13, 2024	Scotiabank	Sector Perform	Sector Perform	Hold
Oct 24, 2024	UBS		Buy	Initialise
Aug 15, 2024	Cowen & Co.	Buy	Buy	Hold
Aug 15, 2024	Citigroup	Buy	Buy	Hold
Aug 15, 2024	H.C. Wainwright	Buy	Buy	Hold
Aug 15, 2024	Barclays	Overweight	Overweight	Hold
Jul 30, 2024	Bank of America Securities	Buy	Buy	Hold
Jun 28, 2024	Jefferies		Buy	Initialise
May 09, 2024	Citigroup	Buy	Buy	Hold
Jul 26, 2023	Citigroup	Buy	Buy	Hold
Jul 11, 2023	Guggenheim		Buy	Initialise
Dec 12, 2022	Goldman Sachs	Buy	Buy	Hold

Syndax Pharmaceuticals's last stock rating was published by Scotiabank on Nov 13, 2024. The company gave SNDX a "Sector Perform" rating, the same as its previous rate.

Syndax Pharmaceuticals Financial Forecast

Syndax Pharmaceuticals Revenue Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	$126.58M	$12.38M	$379.00K	$379.00K	$379.00K	$379.00K	$379.00K	$379.00K	$379.00K	$379.00K	$379.00K	$379.00K	$379.00K	$305.00K	$305.00K
Avg Forecast	$51.34M	$28.52M	$21.28M	$16.46M	$25.20M	$9.32M	$142.86K	$142.86K	$600.00K	$1.33M	$750.00K	$1.38M	$2.56M	$6.29M	$29.41M	$225.00K	$225.00K	$100.00K	$200.00K	$390.00K	$384.75K	$364.50K	$364.50K	$371.60K	$364.75K	$460.56K	$300.70K	$1.08M
High Forecast	$110.58M	$61.43M	$45.84M	$24.88M	$50.45M	$20.07M	$307.70K	$307.70K	$1.29M	$2.87M	$750.00K	$1.38M	$2.56M	$6.29M	$29.41M	$225.00K	$225.00K	$100.00K	$200.00K	$390.00K	$384.75K	$364.50K	$364.50K	$371.60K	$364.75K	$552.67K	$360.84K	$1.30M
Low Forecast	$14.06M	$7.81M	$5.83M	$8.05M	$925.66K	$2.55M	$39.11K	$39.11K	$164.28K	$365.07K	$750.00K	$1.38M	$2.56M	$6.29M	$29.41M	$225.00K	$225.00K	$100.00K	$200.00K	$390.00K	$384.75K	$364.50K	$364.50K	$371.60K	$364.75K	$368.44K	$240.56K	$864.67K
# Analysts	1	1	1	3	8	4	5	4	4	4	3	3	3	4	4	4	7	9	9	9	9	13	13	13	13	15	16	12
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	20.12%	0.42%	1.68%	1.68%	3.79%	1.90%	0.97%	0.99%	1.04%	1.04%	1.02%	1.04%	0.82%	1.01%	0.28%

Syndax Pharmaceuticals's average Quarter revenue forecast for Mar 22 based on 3 analysts is $2.56M, with a low forecast of $2.56M, and a high forecast of $2.56M. SNDX's average Quarter revenue forecast represents a -97.98% decrease compared to the company's last Quarter revenue of $126.58M (Dec 21).

Syndax Pharmaceuticals EBITDA Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	3	8	4	5	4	4	4	3	3	3	4	4	4	7	9	9	9	9	13	13	13	13	15	16	12
EBITDA	-	-	-	-	-	-	-	-	$-46.02M	$-42.03M	$-33.65M	$-36.87M	$-36.51M	$96.21M	$-19.98M	$-22.27M	$-27.08M	$-19.77M	$-19.78M	$-16.40M	$-14.76M	$-13.55M	$-12.83M	$-14.92M	$-14.12M	$-19.34M	$-12.96M	$-10.28M
Avg Forecast	$2.00M	$1.11M	$831.16K	$642.90K	$984.34K	$363.94K	$5.58K	$5.58K	$23.43K	$52.07K	$28.15K	$51.61K	$96.18K	$236.16K	$1.10M	$8.45K	$-31.67M	$3.75K	$7.51K	$14.64K	$-13.32M	$13.68K	$13.68K	$13.95K	$-14.88M	$-22.76M	$-12.78M	$-36.42M
High Forecast	$4.32M	$2.40M	$1.79M	$971.49K	$1.97M	$783.91K	$12.02K	$12.02K	$50.47K	$112.16K	$28.15K	$51.61K	$96.18K	$236.16K	$1.10M	$8.45K	$-25.33M	$3.75K	$7.51K	$14.64K	$-10.65M	$13.68K	$13.68K	$13.95K	$-11.90M	$-18.21M	$-10.22M	$-29.14M
Low Forecast	$548.95K	$304.96K	$227.58K	$314.31K	$36.15K	$99.65K	$1.53K	$1.53K	$6.42K	$14.26K	$28.15K	$51.61K	$96.18K	$236.16K	$1.10M	$8.45K	$-38.00M	$3.75K	$7.51K	$14.64K	$-15.98M	$13.68K	$13.68K	$13.95K	$-17.85M	$-27.31M	$-15.34M	$-43.70M
Surprise %	-	-	-	-	-	-	-	-	-1963.77%	-807.21%	-1195.23%	-714.32%	-379.56%	407.39%	-18.10%	-2636.71%	0.86%	-5266.99%	-2634.74%	-1120.51%	1.11%	-990.72%	-937.72%	-1069.40%	0.95%	0.85%	1.01%	0.28%

3 analysts predict SNDX's average Quarter EBITDA for Mar 22 to be $96.18K, with a high of $96.18K and a low of $96.18K. This is -99.90% lower than Syndax Pharmaceuticals's previous annual EBITDA (Dec 21) of $96.21M.

Syndax Pharmaceuticals Net Income Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	3	8	4	5	4	4	4	3	3	3	4	4	4	7	9	9	9	9	13	13	13	13	15	16	12
Net Income	-	-	-	-	-	-	-	-	$-36.19M	$-36.31M	$-35.66M	$-37.42M	$-37.48M	$96.20M	$-20.64M	$-22.91M	$-27.72M	$-20.42M	$-20.44M	$-17.06M	$-15.24M	$-14.00M	$-12.83M	$-14.92M	$-14.30M	$-19.40M	$-12.97M	$-10.33M
Avg Forecast	$-71.34M	$-85.66M	$-89.17M	$-90.02M	$-84.21M	$-91.38M	$-77.81M	$-83.60M	$-50.89M	$-55.39M	$-54.15M	$-54.29M	$-54.15M	$-50.02M	$-13.88M	$-60.93M	$-32.41M	$-41.54M	$-37.30M	$-38.02M	$-13.74M	$-36.42M	$-40.14M	$-38.56M	$-15.07M	$-22.83M	$-12.79M	$-36.61M
High Forecast	$-3.99M	$-4.79M	$-4.99M	$-86.04M	$445.62M	$-5.11M	$-4.35M	$-4.68M	$-2.85M	$-3.10M	$-54.15M	$-54.29M	$-54.15M	$-50.02M	$-13.88M	$-60.93M	$-25.93M	$-41.54M	$-37.30M	$-38.02M	$-10.99M	$-36.42M	$-40.14M	$-38.56M	$-12.05M	$-18.27M	$-10.23M	$-29.29M
Low Forecast	$-178.35M	$-214.16M	$-222.93M	$-94.01M	$-1.36B	$-228.46M	$-194.53M	$-209.01M	$-127.24M	$-138.48M	$-54.15M	$-54.29M	$-54.15M	$-50.02M	$-13.88M	$-60.93M	$-38.90M	$-41.54M	$-37.30M	$-38.02M	$-16.49M	$-36.42M	$-40.14M	$-38.56M	$-18.08M	$-27.40M	$-15.34M	$-43.93M
Surprise %	-	-	-	-	-	-	-	-	0.71%	0.66%	0.66%	0.69%	0.69%	-1.92%	1.49%	0.38%	0.86%	0.49%	0.55%	0.45%	1.11%	0.38%	0.32%	0.39%	0.95%	0.85%	1.01%	0.28%

Syndax Pharmaceuticals's average Quarter net income forecast for Mar 22 is $-54.15M, with a range of $-54.15M to $-54.15M. SNDX's average Quarter net income forecast represents a -156.29% decrease compared to the company's last Quarter net income of $96.20M (Dec 21).

Syndax Pharmaceuticals SG&A Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	3	8	4	5	4	4	4	3	3	3	4	4	4	7	9	9	9	9	13	13	13	13	15	16	12
SG&A	-	-	-	-	-	-	-	-	$11.96M	$10.19M	$8.24M	$7.99M	$6.84M	$6.93M	$6.80M	$5.84M	$5.67M	$4.72M	$5.82M	$6.05M	$5.92M	$5.08M	$3.60M	$3.46M	$3.91M	$4.79M	$3.93M	$4.27M
Avg Forecast	$283.42M	$157.45M	$117.50M	$90.88M	$139.15M	$51.45M	$788.68K	$788.68K	$3.31M	$7.36M	$4.14M	$7.59M	$14.15M	$34.73M	$162.38M	$1.24M	$1.24M	$552.08K	$1.10M	$2.15M	$2.12M	$2.01M	$2.01M	$2.05M	$2.01M	$2.54M	$1.66M	$5.97M
High Forecast	$610.46M	$339.14M	$253.08M	$137.33M	$278.52M	$110.82M	$1.70M	$1.70M	$7.13M	$15.86M	$4.14M	$7.59M	$14.15M	$34.73M	$162.38M	$1.24M	$1.24M	$552.08K	$1.10M	$2.15M	$2.12M	$2.01M	$2.01M	$2.05M	$2.01M	$3.05M	$1.99M	$7.16M
Low Forecast	$77.60M	$43.11M	$32.17M	$44.43M	$5.11M	$14.09M	$215.94K	$215.94K	$906.96K	$2.02M	$4.14M	$7.59M	$14.15M	$34.73M	$162.38M	$1.24M	$1.24M	$552.08K	$1.10M	$2.15M	$2.12M	$2.01M	$2.01M	$2.05M	$2.01M	$2.03M	$1.33M	$4.77M
Surprise %	-	-	-	-	-	-	-	-	3.61%	1.38%	1.99%	1.05%	0.48%	0.20%	0.04%	4.70%	4.57%	8.55%	5.27%	2.81%	2.79%	2.53%	1.79%	1.69%	1.94%	1.88%	2.37%	0.72%

Syndax Pharmaceuticals's average Quarter SG&A projection for Mar 24 is $788.68K, based on 4 Wall Street analysts, with a range of $215.94K to $1.70M. The forecast indicates a -93.41% fall compared to SNDX last annual SG&A of $11.96M (Mar 23).

Syndax Pharmaceuticals EPS Forecast

	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19	Mar 19	Mar 18	Mar 17	Mar 16
# Analysts	1	1	1	3	8	4	5	4	4	4	3	3	3	4	4	4	7	9	9	9	9	13	13	13	13	15	16	12
EPS	-	-	-	-	-	-	-	-	$-0.52	$-0.57	$-0.59	$-0.62	$-0.64	$1.81	$-0.40	$-0.44	$-0.54	$-0.44	$-0.46	$-0.42	$-0.56	$-0.44	$-0.41	$-0.47	$-0.53	$-0.79	$-0.71	$-2.85
Avg Forecast	$-0.83	$-1.00	$-1.04	$-1.05	$-0.99	$-1.07	$-0.91	$-0.98	$-0.60	$-0.65	$-0.64	$-0.64	$-0.64	$-0.59	$-0.16	$-0.71	$-0.65	$-0.49	$-0.44	$-0.45	$-0.50	$-0.43	$-0.47	$-0.45	$-0.56	$-1.13	$-0.69	$-1.70
High Forecast	$-0.05	$-0.06	$-0.06	$-1.01	$5.22	$-0.06	$-0.05	$-0.05	$-0.03	$-0.04	$-0.64	$-0.64	$-0.64	$-0.59	$-0.16	$-0.71	$-0.65	$-0.49	$-0.44	$-0.45	$-0.50	$-0.43	$-0.47	$-0.45	$-0.56	$-0.90	$-0.55	$-1.36
Low Forecast	$-2.09	$-2.51	$-2.61	$-1.10	$-15.94	$-2.67	$-2.28	$-2.45	$-1.49	$-1.62	$-0.64	$-0.64	$-0.64	$-0.59	$-0.16	$-0.71	$-0.65	$-0.49	$-0.44	$-0.45	$-0.50	$-0.43	$-0.47	$-0.45	$-0.56	$-1.36	$-0.83	$-2.04
Surprise %	-	-	-	-	-	-	-	-	0.87%	0.88%	0.93%	0.97%	1.01%	-3.09%	2.46%	0.62%	0.83%	0.90%	1.05%	0.94%	1.12%	1.03%	0.87%	1.04%	0.95%	0.70%	1.03%	1.68%

According to 3 Wall Street analysts, Syndax Pharmaceuticals's projected average Quarter EPS for Mar 22 is $-0.64, with a low estimate of $-0.64 and a high estimate of $-0.64. This represents a -135.08% decrease compared to SNDX previous annual EPS of $1.81 (Dec 21).

Syndax Pharmaceuticals Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
STRO	Sutro Biopharma	$2.09	$13.00	522.01%	Buy
KROS	Keros Therapeutics	$18.00	$102.00	466.67%	Buy
INZY	Inozyme Pharma	$2.94	$16.00	444.22%	Buy
AVTE	Aerovate Therapeutics	$2.56	$13.00	407.81%	Hold
LRMR	Larimar Therapeutics	$4.32	$17.00	293.52%	Buy
CGEM	Cullinan Oncology	$11.49	$34.00	195.91%	Buy
KALV	KalVista Pharmaceuticals	$8.65	$22.67	162.08%	Buy
PLRX	Pliant Therapeutics	$14.37	$35.50	147.04%	Buy
MLYS	Mineralys Therapeutics	$12.35	$30.00	142.91%	Buy
SNDX	Syndax Pharmaceuticals	$13.63	$31.67	132.36%	Buy
COGT	Cogent Biosciences	$8.19	$16.00	95.36%	Buy
CYTK	Cytokinetics	$47.78	$90.00	88.36%	Buy
DYN	Dyne Therapeutics	$26.16	$49.00	87.31%	Buy
MRUS	Merus	$44.90	$81.25	80.96%	Buy
PCVX	Vaxcyte	$89.86	$148.80	65.59%	Buy
REPL	Replimune Group	$11.72	$19.00	62.12%	Buy
EWTX	Edgewise Therapeutics	$30.17	$46.25	53.30%	Buy
MRSN	Mersana Therapeutics	$2.03	$3.00	47.78%	Buy
RVMD	Revolution Medicines	$45.16	$65.67	45.42%	Buy
VRDN	Viridian Therapeutics	$20.82	$22.75	9.27%	Buy

SNDX Forecast FAQ

Is Syndax Pharmaceuticals a good buy?

Yes, according to 10 Wall Street analysts, Syndax Pharmaceuticals (SNDX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 9 'Buy' recommendations, accounting for 90.00% of SNDX's total ratings.

What is SNDX's price target?

Syndax Pharmaceuticals (SNDX) average price target is $31.67 with a range of $18 to $37, implying a 142.13% from its last price of $13.08. The data is based on 10 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will Syndax Pharmaceuticals stock go up soon?

According to Wall Street analysts' prediction for SNDX stock, the company can go up by 142.13% (from the last price of $13.08 to the average price target of $31.67), up by 182.87% based on the highest stock price target, and up by 37.61% based on the lowest stock price target.

Can Syndax Pharmaceuticals stock reach $20?

SNDX's average twelve months analyst stock price target of $31.67 supports the claim that Syndax Pharmaceuticals can reach $20 in the near future.

What are Syndax Pharmaceuticals's analysts' financial forecasts?

Syndax Pharmaceuticals's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $34.81M (high $71.14M, low $3.56M), average EBITDA is $1.36M (high $2.78M, low $138.85K), average net income is $-337M (high $431.47M, low $-1.993B), average SG&A $192.17M (high $392.73M, low $19.63M), and average EPS is $-3.945 (high $5.05, low $-23.333). SNDX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $117.6M (high $242.72M, low $35.74M), average EBITDA is $4.59M (high $9.48M, low $1.4M), average net income is $-336M (high $-99.811M, low $-709M), average SG&A $649.25M (high $1.34B, low $197.31M), and average EPS is $-3.935 (high $-1.168, low $-8.304).

Did the SNDX's actual financial results beat the analysts' financial forecasts?

Based on Syndax Pharmaceuticals's last annual report (Dec 2021), the company's revenue was $139.71M, beating the average analysts forecast of $36.15M by 286.43%. Apple's EBITDA was $26.22M, missing the average prediction of $-30.319M by -186.48%. The company's net income was $24.93M, missing the average estimation of $-157M by -115.85%. Apple's SG&A was $25.24M, missing the average forecast of $199.6M by -87.35%. Lastly, the company's EPS was $0.48, missing the average prediction of $-2.113 by -122.72%. In terms of the last quarterly report (Dec 2021), Syndax Pharmaceuticals's revenue was $126.58M, beating the average analysts' forecast of $6.29M by 1911.80%. The company's EBITDA was $96.21M, beating the average prediction of $236.16K by 40638.83%. Syndax Pharmaceuticals's net income was $96.2M, missing the average estimation of $-50.02M by -292.32%. The company's SG&A was $6.93M, missing the average forecast of $34.73M by -80.06%. Lastly, the company's EPS was $1.81, missing the average prediction of $-0.587 by -408.57%